Effectiveness of Factor IX Complex Concentrate in Reversing Warfarin Associated Coagulopathy for Intracerebral Hemorrhage
- 308 Downloads
The objective of this study is to show the effectiveness of Factor IX complex concentrate (FIXCC) for rapid reversal of an elevated International Normalized Ratio (INR) in patients with anticoagulation-associated intracerebral hemorrhage (AAICH).
We, retrospectively, analyzed the clinical data of 19 patients with the diagnosis of AAICH from January 2005 to May 2006. A comparison was made among patients treated with FFP and Vit.K [FFP-group (n = 9)] and patients treated with FIXCC in addition to FFP and Vit.K [FIXCC-group (n = 10)]. INR of 1.4 or less was taken as target.
Mean INR on admission for FFP and FIXCC group was 1.84 ± 0.31 and 2.44 ± 1.48, respectively (P = 0.315). After administration of therapy, the INR was reduced from 1.84 ± 0.31 to 1.34 ± 0.08 (P < 0.05) in FFP group and 2.44 ± 1.48 to 1.34 ± 0.07 (P < 0.005) in FIXCC group. Three patients in FFP group (33%) and 8 patients in FIXCC group (80%) reached their target INR in 3–4 h after initiation of therapy (P = 0.012). Mean time taken by both FFP and FIXCC groups to reach the target INR was 8.52 ± 5.60 h and 4.25 ± 2.12 h, respectively (P < 0.05). The mean rate of INR correction was 0.06 ± 0.03 and 0.27 ± 0.25 per hour for the FFP and FIXCC group, respectively (P < 0.005). There was one death in FIX group and two in FFP group and no thrombotic complications.
Our data suggests that FIXCC in combination with FFP and Vit.K may result in decreased time required when compared to FFP and Vit.K alone for correction of warfarin associated coagulopathy in neurosurgical emergencies.
KeywordsWarfarin Factor IX complex concentrate International Normalized Ratio Intracerebral hemorrhage Profilnine SD® Prothrombin complex concentrate
- 6.Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. Neuroepidemiology 2003;22(2):106–17.Google Scholar
- 11.Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006;37(6):1465–70.PubMedCrossRefGoogle Scholar
- 14.Guideline for the use of fresh-frozen plasma. Medical Directors Advisory Committee, National Blood Transfusion Council. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1998;88(10):1344–7.Google Scholar
- 20.Guidelines on oral anticoagulation. Br J Haematol 1998;101.Google Scholar
- 21.Factor IX complex Profilnine® SD Solvent Detergent Treated. In: Grifols Biologicals Inc; January 2004.Google Scholar
- 22.Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84(3):732–47.Google Scholar
- 40.Deveras RAE, Kessler CM. Recombinant factor VIIa (rFVIIa) successfully and rapidly corrects the excessively high international normalized ratio (INR) and prothrombin times induced by warfarin. Blood 2000;96:638.Google Scholar